PPARG

(redirected from PPAR gamma)

PPARG

A gene on chromosome 3p25 that encodes a member of the nuclear receptor family of ligand-activated transcription factors, which heterodimerise with the retinoic X receptor (RXR) to regulate gene expression. PPARG binds peroxisome proliferators such as hypolipidaemic drugs and fatty acids, and controls the peroxisomal beta-oxidation pathway of fatty acids. It is a key regulator of adipocyte differentiation and glucose homeostasis.

Molecular pathology
Defects in PPARG mutation are linked to type-2 insulin-resistant diabetes and hypertension, obesity, glioma type 1, and cause familial partial lipodystrophy type 3.

peroxisome proliferator-activated receptor-gamma gene

,

PPARG

A gene with an allele that increases the risk of developing type 2 diabetes mellitus. People with this allele may benefit from treatment with thiazolidinedione drugs.
References in periodicals archive ?
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.
A dual PPAR agonist, Lipaglyn(TM) has a predominant affinity to PPAR alpha and moderate affinity to PPAR gamma.
Growth arrest (40%) and PPAR gamma mRNA and protein upregulation was achieved with gamma-tocopherol within 6 h.
For the study, the researchers introduced MCPIP to living cells from mice that had been stripped of the PPAR gamma gene and found that the cells still completed the developmental process necessary to build fat.
with overexpresssion of HER2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR gamma ligands, and patients affected with cancer associated with overexpression of at least one member of the class I family of receptor tyrosine kinases selected from the group consisting of HER-2/neu and epidermal growth factor rector, comprising administering to said patient a therapeutically effective amount of a ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma) which has a pKi of at least 4.
Together, these manuscripts establish that MLR-1023 is a next generation insulin sensitizer that works independently of PPAR gamma inhibition.
With a predominant affinity to PPAR alpha isoform and moderate affinity to PPAR gamma isoform of PPAR nuclear receptor subfamily, the molecule has shown beneficial effects on lipids and glycemic control without side effects.